BLTE: Belite Bio, Inc
Performance
BLTE +39.31%
Watchlist
Select an item
Summary
BLTE at a glance
BLTE returned +39.31% over the past year. Its worst drop in that year was -29.10%, smaller than 60% of stocks on Redstone, and its Sharpe ratio of 0.82 beats 67% of stocks on Redstone. It pays no dividends.
Current Drawdown
-18.55%
Rolling Volatility
54.61%
Actions
Metrics
Risk Indicators
Alpha33.68%
Beta1.05x
Sharpe0.82
Sortino1.28
Omega1.15
Calmar1.35
Martin2.83
Profile
About BLTE
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1).
- Sector
- Health Care
- Market cap
- $6.4B
- Listed
- Apr 2022
- Employees
- 41
- Website
- belitebio.com
Comparisons